Report Highlights

Who Controls This Market — And Who Is Threatening That Control

Foundation Medicine, acquired by Roche in 2018 for USD 2.4 billion, controls the comprehensive genomic profiling segment with its FoundationOne CDx — the most widely approved tissue-based CGP assay with FDA approval across 324 genes and regulatory approval as a companion diagnostic for multiple targeted therapies from AstraZeneca, Pfizer, Novartis, and others. Its network of pharmaceutical partnerships — providing genomic profiling data that supports companion diagnostic development and clinical trial patient selection — creates a data assets moat that independent testing companies cannot replicate without the pharmaceutical R&D relationships that Roche provides. Guardant Health is the liquid biopsy market leader for treatment monitoring applications, with its Guardant360 CDx as the FDA-approved ctDNA companion diagnostic for EGFR mutation detection in non-small cell lung cancer and a portfolio of oncology applications covering progression monitoring, treatment selection, and MRD detection across multiple tumour types.

The threat to established positions comes from multi-cancer early detection — the emerging category that could be the largest liquid biopsy application if clinical utility and reimbursement are demonstrated. Grail (acquired by Illumina, then spun out under antitrust pressure) has the most advanced multi-cancer early detection programme with its Galleri test, which detects 50+ cancer types from a single blood draw using methylation signatures. CMS coverage determination for Galleri — expected in 2025–2026 — would transform the market by providing reimbursement for annual screening in the average-risk population, creating a USD 20+ billion US addressable market for a test currently priced at USD 949 per screen without insurance coverage.

Industry Snapshot

Precision oncology diagnostics uses genomic sequencing and molecular analysis to characterise individual tumours at the molecular level, enabling treatment decisions based on a patient's specific tumour biology rather than tumour type and stage alone. The two primary diagnostic modalities are tissue-based comprehensive genomic profiling (CGP) — which analyses tumour DNA from biopsy samples using next-generation sequencing to identify actionable mutations, copy number alterations, and gene fusions — and liquid biopsy — which analyses circulating tumour DNA, RNA, and cells shed from tumours into the bloodstream, enabling non-invasive and repeatable molecular profiling without repeat tissue biopsies. The clinical utility of CGP is established for guiding targeted therapy selection across lung, breast, colorectal, bladder, and ovarian cancers, with FDA-approved companion diagnostic labelling for over 50 targeted therapies as of 2025. Liquid biopsy's clinical utility is most firmly established for treatment monitoring and MRD assessment in haematological malignancies and is rapidly accumulating evidence in solid tumours for recurrence detection and treatment response monitoring.

The Forces Accelerating Demand Right Now

Targeted therapy pipeline expansion is the primary demand driver — the pharmaceutical industry's oncology pipeline has shifted decisively toward biomarker-selected targeted therapies, with over 60% of oncology Phase 3 trials in 2024 including biomarker-driven patient selection requirements. Every new targeted therapy approval creates a companion diagnostic opportunity for the genomic profiling test that identifies eligible patients, and the oncology drug pipeline contains 400+ late-stage targeted therapy programmes that will each require companion diagnostic development and regulatory approval over the next 5–10 years. CMS and commercial insurer reimbursement expansion for CGP is normalising genomic profiling as a standard diagnostic step in solid tumour workup — CMS's Molecular Diagnostic Services MolDX programme covers FoundationOne CDx for all solid tumour types in Medicare beneficiaries, providing a USD 3,500 reimbursement that makes routine CGP economically viable for oncology practices. The MRD monitoring market in multiple myeloma, chronic lymphocytic leukaemia, and acute myeloid leukaemia is the fastest-growing liquid biopsy application, with clinical evidence demonstrating MRD negativity as a prognostic marker and treatment endpoint that payers are increasingly recognising for reimbursement.

What Is Holding This Market Back

Reimbursement remains inadequate for many precision oncology applications outside the US. European national health systems — the NHS, CPAM (France), GKV (Germany) — provide limited reimbursement for comprehensive genomic profiling except through specific national cancer genomics programmes, creating significant market access fragmentation that limits revenue outside the US market. Turnaround time and tissue quantity requirements for tissue-based CGP create clinical workflow challenges — Foundation One CDx requires 14 business days for results at a time when treatment initiation cannot wait, and the 10% tumour cellularity requirement for accurate mutation calling means a significant fraction of biopsies provide inadequate material. For liquid biopsy, circulating tumour DNA levels are often below reliable detection thresholds at early cancer stages and in post-treatment minimal residual disease states, limiting assay sensitivity precisely when clinical decisions are most time-sensitive. Multi-cancer early detection faces the specific challenge that high test sensitivity for uncommon cancers (low-prevalence in screening populations) creates insufficient positive predictive value even at high specificity — a screening test that is 99% specific across 50 cancer types still has a false positive rate in a population where most cancers are rare that generates more false positives than true positives in average-risk individuals.

The Investment Case: Bull, Bear, and What Decides It

The bull case projects comprehensive genomic profiling becoming standard of care in all solid tumour oncology within 5 years, creating a USD 15–20 billion annual US market from 2 million annual solid tumour diagnoses at USD 3,500 reimbursement per test. Multi-cancer early detection adds a further USD 20+ billion addressable market if CMS provides annual screening reimbursement for the 50 million Americans in the Grail Galleri clinical population — a US screening market comparable in size to colonoscopy or mammography programmes. At these scale projections, the precision oncology diagnostics market is one of the largest addressable markets in medical technology.

The bear case observes that reimbursement timelines consistently run 5–10 years longer than industry projections, and that the positive predictive value limitations of multi-cancer early detection in average-risk populations create a clinical economics problem that may limit reimbursement to high-risk subpopulations rather than universal screening. Guardant Health's revenue growth has been positive but below projections in multiple years, reflecting the gap between market narrative and actual reimbursement expansion timelines. The decisive variable for the next growth cycle is CMS coverage determination for Galleri MCED — approval would add USD 5+ billion in near-term revenue potential; denial or conditional coverage limited to high-risk groups would reset market projections significantly downward.

Where the Next USD Billion Is Being Built

AI-driven pathology — using deep learning models to extract genomic and molecular information from standard haematoxylin-and-eosin stained tissue slides without requiring sequencing — is a USD 2–4 billion emerging market that could expand precision oncology to resource-limited settings where sequencing infrastructure is unavailable. Paige AI, PathAI, and Aignostics are developing AI pathology models that predict biomarker status, prognosis, and treatment response from routine pathology slides, potentially democratising access to precision diagnostics beyond the current sequencing-dependent market. Proteomics-based liquid biopsy — using plasma protein profiles rather than ctDNA for cancer detection and monitoring — is a complementary approach with different sensitivity/specificity characteristics being developed by SomaLogic (now Standard BioTools), Olink Proteomics (acquired by Thermo Fisher), and Nautilus Biotechnology.

Market at a Glance

Regional Intelligence

North America accounts for approximately 55% of global precision oncology diagnostics revenue, driven by the highest FDA companion diagnostic approval density, the most advanced CMS reimbursement framework for molecular diagnostics, and the concentration of pharmaceutical R&D that generates companion diagnostic development contracts. Europe is the second-largest market but is structurally fragmented across national reimbursement systems, with the UK's NHS Genomics Medicine Service (providing whole genome sequencing for rare cancers), France's INCa national cancer genomics programme, and Germany's NCT programme representing national approaches that lack the scale of the US MolDX reimbursement pathway. Asia-Pacific is the fastest-growing precision oncology diagnostics market, led by Japan (health insurance coverage for genomic profiling in approved cancer types), China (domestic CGP companies including Burning Rock, Genetron, and Berry Oncology accessing the world's largest cancer patient population), and South Korea (HIRA reimbursement for NGS-based cancer testing).

Leading Market Participants

• Foundation Medicine
• Guardant Health
• Illumina
• Exact Sciences
• Tempus AI

Long-Term Market Perspective

By 2034, comprehensive genomic profiling will be standard of care for all solid tumour diagnoses in developed markets, liquid biopsy MRD monitoring will be integrated into treatment protocols for haematological and solid tumour oncology, and multi-cancer early detection will have defined its reimbursement position in high-risk population screening. The market will be increasingly dominated by integrated precision oncology platforms — combining sequencing, AI interpretation, clinical data, and therapeutic decision support — rather than standalone diagnostic services. The companies best positioned for this integrated future are those that own large linked clinical-genomic datasets, which improve AI model quality with each new patient case added — a data flywheel that Foundation Medicine (with Roche's pharmaceutical clinical trial data), Tempus AI (with its EHR-linked genomic database), and Guardant Health (with its liquid biopsy longitudinal monitoring database) are each building with different data sources and different competitive implications.